You are here: Industry Insights > RRP

News List

First Patient Dosed for AdenoVerse Immunotherapy for Recurrent Respiratory Papillomatosis americanpharmaceuticalreview
March 30, 2021
Precigen announced the first patient has been dosed in the Phase I study of PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) AdenoVerse™ immunotherapy in adult patients with recurrent respiratory papillomatosis (RRP).
Precigen Receives Orphan Drug Designation for PRGN-AdenoVerse™ Immunotherapy for Respiratory Papillomatosis americanpharmaceuticalreview
March 24, 2021
Precigen announced the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) AdenoVerse™ immunotherapy for recurrent respiratory papillomatosis (RRP).
Precigen Announces IND to Begin Study of AdenoVerse Immunotherapy for RRP americanpharmaceuticalreview
January 13, 2021
Precigen announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to initiate a Phase I clinical trial of Precigen's PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) ...
INOVIO Receives Orphan Drug Designation for Recurrent Respiratory papillomatosis Treatment americanpharmaceuticalreview
August 05, 2020
INOVIO announced the U.S. Food and Drug Administration (FDA) granted orphan drug designation for INO-3107, its DNA medicine being evaluated in a Phase 1/2 trial for treatment of recurrent respiratory papillomatosis (RRP).